Business Wire

MA-GILLETTE

31.5.2023 15:31:33 CEST | Business Wire | Press release

Share
Gillette Celebrates Return of Gillette Cup Featuring Fortnite With All-Star Gillette Gaming Alliance

Gillette (NYSE: PG), the world’s largest male grooming company and brand pioneer in gaming and esports, proudly announced the return of the highly anticipated Gillette Cup Featuring Fortnite, a two-day international gaming competition featuring a custom-built island in Fortnite. First played in February 2022, the inaugural Gillette Cup garnered over 300,000 viewing hours throughout the tournament. Back for its second year, the event kicks off on June 1, 2023, and will unite members of the Gillette Gaming Alliance as they compete against members of the global Fortnite community for $50,000 -- doubling the prize pool from last year. The Gillette Cup Featuring Fortnite is among one of the largest branded tournaments to date for the gaming community.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230531005178/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Gillette celebrates return of Gillette Cup Featuring Fortnite with all-star Gillette Gaming Alliance. (Photo: Business Wire)

The competition will be played on a revamped “Gillette Face-Off” island, a custom environment developed using Fortnite’s Creative toolset; this builds on the success of the island’s existing futuristic lab and mineshaft versions, which were first introduced in 2022. The custom branded Fortnite islands feature action-packed “Zero Build” gameplay and iconic Gillette products for a gaming experience as satisfying as a close shave. To compete in the “Gillette Face-Off” islands at any time, use island code 6674-8139-7577.

“The celebrated return of the Gillette Cup Featuring Fortnite is testament to our previous successes and deepening relationship with Gillette Gaming Alliance members to provide meaningful and impactful experiences to the gaming community,” explains Daniel Ordonez, Gillette Global Brand Franchise Leader. “We are looking forward to cheering on our Alliance members and engaging with Fortnite’s community – while, most importantly, meeting them where they thrive in a truly fun and authentic way.”

For the first time, viewers and fans worldwide can visit www.GilletteCup.com to check out the leaderboard and tune-in for real-time updates. Additionally, they will have the chance to win exclusive Gillette Gaming gear and products by visiting the newly launched website throughout the tournament.

Tournament Details – Competitive, Professional Sporting Event Style Format

The tournament will kick off with the Regionals Round, where eight (8) teams of “Duos,” representing eight (8) countries/regions will compete – totaling 64 teams and 128 players across the globe. Participants will represent Brazil, France, Germany, Italy, Mexico, Spain, United Kingdom, and USA/Canada. Using a points system, teams will be randomly placed on the “Gillette Face-Off” island and compete in multiple rounds of Zero Build matches.

The top 16 teams from Regionals will compete for the opportunity to advance to Semi-Finals and be divided into two (2) groups of eight (8) Duos. These 16 teams will continue to compete in multiple rounds of the “Gillette Face-Off” island. The top four (4) Duos from each group will advance to the Finals to form a single lobby and compete in multiple rounds of the Gillette Cup custom island. The Duos will be scored using the points system and awarded cash prizing, based on how they rank. The last Duo standing will be named winner of the Gillette Cup!

Gillette Gaming Alliance members – inclusive of TypicalGamer (USA/Canada), Vicens (Spain), Agustin (Spain), Papaplatte (Germany), Rumathra (Germany), Elded (Mexico), Jolavanille (France), Pizfn (Italy), Xuider (Italy), Mongraal (United Kingdom), and Nobru (Brazil) – will represent their respective countries as they battle it out against fellow professional members of the Fortnite community to bring home the “win” and championship prize.

“I have had a blast streaming for the Gillette Gaming Alliance this year and providing awesome content and experiences to my community on behalf of the brand,” shares Fortnite pro Andre Rebelo, also known as TypicalGamer, Gillette Gaming Alliance member representing North America. “I remember tuning into the Gillette Cup last year and thinking it was epic. So, I am really excited to be a part of it myself this year – and I hope to bring home the W for my fans and followers.”

The Gillette Gaming Alliance, now in its fifth year, serves as Gillette’s longest running gaming activation as well as one of the most defining and successful programs to date for the brand.

*This is an independently created Fortnite Creative experience and is not sponsored, endorsed, or administered by Epic Games, Inc.

About Gillette

For more than 120 years, Gillette has delivered precision technology and unrivaled product performance – improving the lives of over 800 million consumers around the world. From shaving and body grooming, to skin care and sweat protection, Gillette offers a wide variety of products including razors, shave gel (gels, foams and creams), skin care, after shaves, antiperspirants, deodorants and body wash. For more information and the latest news on Gillette, visit www.gillette.com. To see our full selection of products, visit www.gillette.com. Follow Gillette on Twitter, Facebook and Instagram.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper® The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230531005178/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye